Lts Lohmann Therapie-Systeme Ag

Lts Lohmann Therapie-Systeme Gmbh

Lts Lohmann Therapie-Systeme Gmbh + Co. Kg

Schwarz Pharma Ag

Other

Merck Patent Gmbh

Lohmann Gmbh & Co Kg

Sanol Schwarz Gmbh

Lts Lohmann Therapie-Systems Gmbh & Co. Kg

Lts Lohmann Therapie-Systemme Gmbh & Co. Kg

Lts Lohmann Therapie-Systeme Bmgh & Co., Kg

Reinhold Meconi

Frank Seibertz

Robert-Peter Klein

Hans-Rainer Hoffmann

Halvor Jaeger

Michael Horstmann

Klaus Schumann

Robert P Klein

Tina Rademacher

Rainer Lichtenberger

Hans-Michael Wolff

Walter Müller

Hans R Hoffmann

Elvira Kirstgen

Hans M Wolff

Henning Von Knobelsdorff

Ursula G&ouml;tte

Dieter Beutner

Rainer Hoffmann

Robert-Pieter Klein

Sylvia Hahn

Horst Zerbe

Michael Wolff

Hans-Ranier Hoffmann

Gunter Cordes

The present invention is directed to transdermal therapeutic systems that are free of fibrous constituents, as well methods for producing such transdermal therapeutic systems. A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system. Exemplary printing methods include application methods based upon a distributor plate of an application device.

Fibre-free transdermal therapeutic system and method for its production

A transdermal therapeutic system which is free of fibrous constituents, and a method for the production of such a transdermal therapeutic system A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system.

A transdermal therapeutic system in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising a backing layer, a reservoir supersaturated with active ingredients which is attached to said backing layer and prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, and a detachable protective layer, is characterized in that the crystallization inhibitor is an amino-containing polymer.

Transdermal therapeutic system containing hormones and crystallization inhibitors

A dermal or transdermal therapeutic system comprising a sheet-like substrate or reservoir containing readily volatile auxiliary agents or active agents, which substrate or reservoir is covered on one of its sides with a backing layer impermeable to the ingredients and on the opposite side with a detachable, likewise impermeable protective layer to prevent loss of ingredients during prolonged storage, is characterized in that both the backing layer and the protective layer are made of plastic film which is on both sides with vapour-deposited metal

Plastic films, especially for use in a dermal or transdermal therapeutic system

An active substance-containing patch for controlled release of estradiol or its pharmaceutically acceptable derivatives, alone or in combination with gestagens, to the human or animal skin, consisting of a backing layer, an active substance-containing reservoir connected thereto which is suitable for combined active substance release and which has been produced using pressure-sensitive adhesives, and a detachable protective layer, is characterized in that the pressure-sensitive adhesive contains wool wax or components thereof and zinc oxide.

Estradiol-containing patch for transdermal application of hormones

An active-substance-containing transdermal therapeutic system for the controlled release of estradiol or its pharmaceutically acceptable able derivatives alone or combined with gestagens consisting of a layer, an active-substance-containing reservoir which is bonded thereto and produced by using pressure sensitive adhesives, and a removable protective layer is characterized by the fact that the pressure sensitive adhesive comprises esters of colophony.

Transdermal therapeutic system containing estradiol

An active compound-containing patch for the controlled delivery of oestradiol or its pharmaceutically acceptable derivatives, alone or in combination with gestagens, to human or animal skin, having an active compound-containing reservoir based on ethylcellulose and contact adhesives comprising adhesive resins is characterized by a contact adhesive having a high plasticizer content.

Transdermal, hormone-delivering therapeutic system

Process for the production, transport and storage of a therapeutic system which is in the form of a plaster and has an active layer supersaturated with active ingredient and containing the active ingredient in homogeneous dispersion or in solution, characterized in that it is carried out avoiding process parameters which favour or induce crystallization of active ingredient, and any type of pressure operating on the plaster and, in particular, on the active layer is avoided while it is carried out.

Method for producing a therapeutic system in the form of plaster

An active-substance-containing transdermal therapeutic system for the controlled release of estradiol or its pharmaceutically acceptable derivatives alone or combined with gestagens consisting of a backing layer, an active-substance-containing reservoir which is bonded thereto and produced by using pressure sensitive adhesives, and a removable protective layer is characterized by the fact that the pressure sensitive adhesive comprises esters of colophony.

Estradiol penetration enhancers

The invention concerns a transdermal therapeutic system comprising the active substance 17-.beta.-estradiol and optionally further active substances, with a laminated structure comprising a backing layer which is substantially impermeable to moisture and impermeable to active substance, one or more matrix layers and, where non-adhesive matrix layers are present, an adhesive layer, characterized in that the concentration of the dissolved estradiol in all matrix layers and, where an adhesive layer is present, in the adhesive layer lies between its saturation concentration in dry condition und its saturation concentration in moist condition, whereby the term 'dry condition' is understood to mean that the base material is in equilibrium with a gas phase with less than 10% relative humidity and the term 'moist condition' is understood to mean that the base material is in equilibrium with a gas phase with more than 90% relative humidity.

Growing community of inventors

Neuwied, Germany

Reinhold Meconi